UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018461
Receipt number R000021380
Scientific Title Comparative evaluation of cellular damages and inflammatory responses between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation
Date of disclosure of the study information 2015/07/28
Last modified on 2015/07/31 17:37:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparative evaluation of cellular damages and inflammatory responses between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Acronym

Comparative evaluation between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Scientific Title

Comparative evaluation of cellular damages and inflammatory responses between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Scientific Title:Acronym

Comparative evaluation between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Region

Japan


Condition

Condition

atrial fibrillation

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We aimed to investigate whether there are the differences of cellular damages, inflammatory responses, oxidative stress, and anticoagulation between cryoballoon catheter and radiofrequency catheter for patients with atrial fibrillation after catheter ablation.

Basic objectives2

Others

Basic objectives -Others

We also aimed to evaluate the predictive biomarkers for recurrence of atrial fibrillation during study periods.

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Degree of cardiac injury (Troponin I)

Key secondary outcomes

The presence or absence of recurrence of atrial fibrillation during study periods.
Time taken to treatment with catheter ablation.
Components of Examination
(CK, CK-MB, Troponin T, HFBP, vWF, thrombomodulin, P-selectin, Endothelin-1, WBC(Neutrophil), CRP, Serum amyloid A, E-selectin, PTX3, sCD40L, ferritin, IL-6, IL-8, TNF-alpha, TGF-beta, IL-4, IL-10, GDF15, D-dimer, TAT, PIC, HANP, BNP, NT Pro-BNP, MDA-LDL, 8-OHdG, MMP-2, TIMP-2, s-FasL)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Interventions: Cryoballoon catheter group
Arctic Front Advance or Freezor MAX cryoballoon catheter

Interventions/Control_2

Control: radiofrequency catheter group
NaviStar ThermoCool ablation catheter

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

Study subjects are atrial fibrillation patients (20-79 years old) who will undergo catheter ablation in University of Tsukuba Hospital, and give written informed consent for the study.

Key exclusion criteria

(1) severe LV dysfunction (LVEF < 35%)
(2) severe mitral valve stenosis
(3) severe atrial valve stenosis
(4) open cardiac surgery within 3 months
(5) percutaneous coronary intervention within 1 months
(6) renal failure patients with hemodialysis
(7) severe anemia (hemoglobin < 10g/dl in men, <9g/dl in women)
(8) complicated with atrial flutter, supraventricular tachycardia, and ventricular tachycardia who are needed to undergo catheter ablation
(9) patients who are likely to have poor prognosis such as terminal cancer
(10) contraindication for catheter ablation (ex. left atrial appendage thrombosis)

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazutaka Aonuma

Organization

University of Tsukuba

Division name

Cardiovascular Division, Faculty of Medicine

Zip code


Address

1-1-1 Tennoudai, Tsukuba, Ibaraki, Japan

TEL

029-853-3142

Email

kaonuma@md.tsukuba.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nobuyuki Murakoshi

Organization

University of Tsukuba

Division name

Cardiovascular Division, Faculty of Medicine

Zip code


Address

1-1-1 Tennoudai, Tsukuba, Ibaraki, Japan

TEL

029-853-3142

Homepage URL


Email

n.murakoshi@md.tsukuba.ac.jp


Sponsor or person

Institute

Cardiovascular Division, Faculty of Medicine, University of Tsukuba

Institute

Department

Personal name



Funding Source

Organization

Medtronic Japan Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

筑波大学(茨城県)


Other administrative information

Date of disclosure of the study information

2015 Year 07 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2015 Year 07 Month 15 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 20 Day

Last follow-up date

2018 Year 05 Month 31 Day

Date of closure to data entry

2019 Year 05 Month 31 Day

Date trial data considered complete

2019 Year 05 Month 31 Day

Date analysis concluded

2019 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 07 Month 28 Day

Last modified on

2015 Year 07 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021380


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name